News
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial ...
BASKING RIDGE, N.J.-- (BUSINESS WIRE)--Jul 9, 2025--TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ...
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial showed a sustained clinical benefit from long-term ...
Final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial showed a sustained clinical benefit from long-term treatment with TURALIO ® (pexidartinib ...
Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell therapies. Read more here.
The Trump family may be having second thoughts about that “Made in the USA” claim attached to its new Trump-branded phone, which raises an interesting question: How to define “made”?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results